Table 1.

Summary of overall pharmacokinetic parameters for subjects taking oral artesunate for 7 days

PK parameter	Geometric mean value for subjects given the following dose of AS:			P valued
	2 mg/kg	4 mg/kg	6 mg/kg
AS on day 0a
t1/2 (h)	0.489	0.499	0.461	0.827
Tmax (h)	0.482	0.518	0.640	0.366
Cmax (μg/liter)	83.1	237	374	<0.0001
AUC0–8 (μg · h/liter)	91.2	279	453	<0.0001
MRT (h)	1.07	1.06	1.17	0.749
V/F (liter/kg)	14.2	10.1	8.56	0.051
CL/F (liter/h/kg)	20.1	13.9	12.9	<0.0001
DHA on day 0b
t1/2 (h)	0.838	0.913	1.13	0.170
Tmax (h)	1.26	1.15	1.44	0.310
Cmax (μg/liter)	554	1,515	2,129	<0.0001
AUC0–8 (μg · h/liter)	1,331	3,854	5,989	<0.0001
MRT (h)	2.06	2.21	2.84	0.008
DHA on day 6c
t1/2 (h)	0.799	0.851	0.843	0.186
Tmax (h)	2.08	2.11	2.17	0.555
Cmax (μg/liter)	196	497	875	<0.0001
AUC0–8 (μg · h/liter)	481	1267	2218	<0.0001
MRT (h)	2.53	2.67	2.64	0.144

^aFor the artesunate (AS) pharmacokinetic (PK) parameters for subjects given AS on day 0, 75, 40, and 28 subjects were given 2, 4, and 6 mg/kg of AS, respectively.

^bFor the dihydroartemisinin (DHA) PK values on day 0, 75, 40, and 27 subjects were given 2, 4, and 6 mg/kg of AS, respectively. One subject was excluded from the 6-mg/kg AS group because of an outlier value.

^cFor the DHA PK values on day 0, 73, 38, and 25 patients were given 2, 4, and 6 mg/kg of AS, respectively. The sample size decreased for all three groups because there are no follow-up data for two subjects.

^dP value for Kruskal-Wallis one-way ANOVA.